Taxotere was selling about US$1b per annum I believe. So do we give the DEP treatment a 20% of selling $500m per annum. That would might give DEP a $US 500m val roughly. Seems a bit out of whack with the SP - lol - so take that with a grain of salt I suggest.
Ann: DEP Docetaxel Trial Dose Exceeds Common Taxotere Dose Level, page-5
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
9.5¢ |
Change
-0.003(3.06%) |
Mkt cap ! $39.17M | |||
| Open | High | Low | Value | Volume |
| 10.0¢ | 10.0¢ | 9.5¢ | $12.55K | 130.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 586785 | 9.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 9.7¢ | 56840 | 1 |
View Market Depth
| Last trade - 16.10pm 23/07/2024 (20 minute delay) ? |
| SPL (ASX) Chart |